Cape Town based vaccine manufacturing hub will see South Africa produce dual antigen Covid-19 vaccines from start to finish. Soon-Shiong, along with Ramaphosa launched the NantSA vaccine manufacturing campus on Wednesday.
This Covid-19 vaccine targets both the mutations prone spike protein of the virus, as well as its nucleocapsid protein. Current vaccines target only the spike protein on the surface of the Covid-19.
Dr Soon-Shiong said the aim is to produce at least one billion doses by 2025.
"We're comfortable that we can do that and the answer to that is, therefore, therein being the largest south amplifying RNA facility in the world". Ramaphosa said.
Around 400 to 600 people will be employed at the production hub. The project will also go hand-in-hand with a R100 million education and training programme in biotechnology and life sciences.
Content created and supplied by: MsTee (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More